AI주식인사이트AI Stock Insight
C

HLB

028300KOSDAQ

49.5 / 100

Reference Date: 2026-10-23

Financial Score17.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 29.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HLB operates in four key sectors: healthcare, biotechnology, shipbuilding, and media commerce. The company produces and sells a range of products, including in-vitro diagnostic medical devices, oncology drugs like Rivoceranib and RLY-4008, specialty ships, and beauty devices. In the biotechnology sector, the company focuses on innovative drug development, while the shipbuilding division designs and manufactures specialty vessels and safety equipment.

Number of Employees

151people

Average Salary

60.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
11.06Industry Average 1.200.0Point

9.2x industry avg (risky)

ROE
-41.07Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
17.82Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲41.2% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲8.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -30.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (36%)

Current 41,050Won52-week high 68,20052-week low 25,650
1-month return6.0Point

1m +29.29% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral전환가액의조정2026-10-15
  • Neutral기타경영사항(자율공시) (HLB 간암 1차 치료제(리보세라닙,캄렐리주맙 병용요법) FDA에 재승인 서류 제출)2026-10-12
  • Neutral기업설명회(IR)개최2026-10-12